Mogamulizumab for cutaneous T- cell lymphoma

Bookmark and Share
Published: 10 Dec 2017
Views: 1884
Prof Youn Kim - Stanford University, Stanford, CA

Prof Kim presents, in a press conference at the ASH 2017 annual meeting, data from a randomized trial looking into mogamulizumab, a monoclonal antibody directed against chemokine receptor 4, for patients with cutaneous T- cell lymphoma.

Read the news story or watch the interview with Dr Horwitz for more.